These results were further corroborated by analyzing public databases obtained from The Cancer Genome Atlas (TCGA; n = 52 tumor and 52 non-tumor adjacent; Figure 1c) data portal, wherein 41 out of 52 samples (78.85%) showed a clear overexpression of EN2, and from the Memorial Sloan Kettering Cancer Center (MSKCC; n = 179) dataset (Figure 1d) which showed higher levels of EN2 mRNA in PCa samples compared to controls. This evidence concerns the gene EN2 and posterior cortical atrophy.